Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
Holding PGEN?
Track your performance easily
PGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $1.93
Previous Close$0.68
Volume1.16M
Average Volume (3M)820.58K
Market Cap
$197.77M
Enterprise Value$149.91M
Total Cash (Recent Filing)$99.29M
Total Debt (Recent Filing)$51.42M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Feb 26, 2025EPS Estimate
-$0.07Last Dividend Ex-Date
Jan 19, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding292,869,097
10 Day Avg. Volume996,710
30 Day Avg. Volume820,577
Standard Deviation0.27
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)7.35
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.57
Enterprise Value/Gross Profit7.29
Enterprise Value/Ebitda-2.46
Forecast
1Y Price Target
$6.00Price Target Upside790.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Precigen News
PremiumCompany Announcements
Precigen Reports Q3 2024 Financial Results
PremiumCompany Announcements
Precigen Regains Full Control of Technology Post Agreement TerminationPremiumCompany Announcements
Precigen Aligns Executive Incentives with FDA Approval Goals
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive data from the pivotal Phase 1/2 study demonstrates the durable efficacy of PRGN-2012 in preventing surgical intervention for recurrent respiratory papillomatosis.
Financial PositionThe company's financial position strengthened with an additional $30 million from an equity financing, enhancing its cash reserves for future developments.
Regulatory ProgressPrecigen is on track to submit a rolling BLA under an accelerated approval pathway for PRGN-2012, with a confirmatory Phase 3 study already initiated.
Bears Say
Equity And Share PriceThe combination of strategic de-prioritization of pipeline programs and recent equity dilution has resulted in a lowered price target, which might reflect decreased investor confidence.
Subsidiary OperationsThe winding down of ActoBio subsidiary operations, along with the planned elimination of its entire workforce, could signal struggles in maintaining or growing certain business segments.
Workforce ReductionA significant reduction of over 20% in the workforce may indicate potential operational challenges and uncertainties for the company.
---
Ownership Overview
42.51% Insiders
12.66% Mutual Funds
12.45% Other Institutional Investors
26.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PGEN FAQ
What was Precigen’s price range in the past 12 months?
Precigen lowest stock price was $0.67 and its highest was $1.93 in the past 12 months.
What is Precigen’s market cap?
Currently, no data Available
When is Precigen’s upcoming earnings report date?
Precigen’s upcoming earnings report date is Feb 26, 2025 which is in 67 days.
How were Precigen’s earnings last quarter?
Precigen released its earnings results on Nov 14, 2024. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.004.
Is Precigen overvalued?
According to Wall Street analysts Precigen’s price is currently Undervalued.
Does Precigen pay dividends?
Precigen pays a Notavailable dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Precigen dividends here
What is Precigen’s EPS estimate?
Precigen’s EPS estimate is -$0.07.
How many shares outstanding does Precigen have?
Precigen has 292,869,100 shares outstanding.
What happened to Precigen’s price movement after its last earnings report?
Precigen reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Precigen?
Among the largest hedge funds holding Precigen’s share is Third Security, Llc. It holds Precigen’s shares valued at 79M.
---
Precigen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (790.74% Upside)
$6.00 (790.74% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.67%
12-Months-Change
Fundamentals
Return on Equity
-137.46%
Trailing 12-Months
Asset Growth
-56.22%
Trailing 12-Months
Company Description
Precigen
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
---
PGEN Earnings Call
Q2 2024
0:00 / 0:00
---
PGEN Stock 12 Month Forecast
Average Price Target
$6.00
▲(790.74% Upside)
Technical Analysis
Best Analysts Covering PGEN
1 Year
1 Year Success Rate
4/25 ratings generated profit
1 Year Average Return
-30.66%
reiterated a buy rating last month
Copying Jason Butler's trades and holding each position for 1 Year would result in 16.00% of your transactions generating a profit, with an average return of -30.66% per trade.
---